Call Us + 33 1 84 88 31 00

Article R1161-25 of the French Public Health Code

The company exploiting the medicinal product produces a follow-up report at the end of each programme or at the latest when it is renewed.

The report is sent to the treating doctor, the prescribing doctor and the Agence nationale de sécurité du médicament et des produits de santé.

Original in French 🇫🇷
Article R1161-25

L’entreprise exploitant le médicament produit un bilan de suivi à la fin de chaque programme ou au plus tard au moment de son renouvellement.

Le bilan est transmis au médecin traitant, au médecin prescripteur et à l’Agence nationale de sécurité du médicament et des produits de santé.


Need help with this article? Get help from a French lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.